Compare VALN & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VALN | TKNO |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.3M | 268.1M |
| IPO Year | 2021 | 2021 |
| Metric | VALN | TKNO |
|---|---|---|
| Price | $6.58 | $6.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | 81.9K | ★ 251.3K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $40,520,000.00 |
| Revenue This Year | N/A | $8.27 |
| Revenue Next Year | $93.87 | $13.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.35 |
| 52 Week Low | $4.75 | $1.91 |
| 52 Week High | $12.23 | $7.84 |
| Indicator | VALN | TKNO |
|---|---|---|
| Relative Strength Index (RSI) | 57.83 | 50.70 |
| Support Level | $5.10 | $4.87 |
| Resistance Level | $7.31 | $7.66 |
| Average True Range (ATR) | 0.23 | 0.37 |
| MACD | -0.05 | -0.12 |
| Stochastic Oscillator | 47.78 | 12.90 |
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.